Astellas Acquires IVERIC bio for Approximately $5.9 Billion
April 29, 2023
Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.
- Buyers
- Astellas Pharma Inc.
- Targets
- IVERIC bio, Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.